Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem Oncology (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company pioneering targeted therapies for cancer treatment, with a specialized focus on inhibiting RAF/MEK and FAK signaling pathways. This dedicated news hub provides investors and industry observers with timely updates on the company's progress in developing innovative solutions for treatment-resistant cancers.
Access comprehensive coverage of Verastem's latest developments including clinical trial milestones, regulatory updates, strategic partnerships, and financial results. Our curated news collection serves as an essential resource for tracking advancements in cancer stem cell research and precision oncology programs.
Find authoritative reporting on key initiatives such as VS-6766 (RAF/MEK inhibitor) developments, combination therapy trials, and intellectual property updates. The page consolidates earnings announcements, research publications, and management commentary for efficient due diligence.
Bookmark this page for direct access to verified information about Verastem's pipeline progress and corporate developments. Check regularly for new updates on therapeutic candidates moving through clinical evaluation and their potential implications for cancer care innovation.
Verastem Oncology (Nasdaq: VSTM) announced its addition to the Russell 3000® and Russell Microcap® Indexes, effective July 1, 2024.
This inclusion reflects the company's progress, including the advancement of avutometinib combined with defactinib for recurrent low-grade serous ovarian cancer. Verastem anticipates announcing mature data from RAMP 201 and completing its rolling NDA submission in the latter half of 2024.
The company is also progressing in the clinical programs for metastatic pancreatic cancer and non-small cell lung cancer. Additionally, GenFleet has initiated a Phase 1/2 clinical trial in China for GFH375/VS-7375, targeting KRAS G12D mutations.
Russell indexes are essential benchmarks for investment managers, encompassing the 4,000 largest U.S. stocks and tracking about $10.5 trillion in assets.
GenFleet Therapeutics has received approval from China's National Medical Products Administration (NMPA) for an open-label, multi-center phase I/II clinical trial of GFH375 (VS-7375), an oral KRAS G12D (ON/OFF) inhibitor, in patients with advanced solid tumors. This trial targets the prevalent KRAS G12D mutation, with no existing G12D-targeted therapies approved. GFH375 has shown promising preclinical safety, bioavailability, and efficacy, including potential for treating brain metastases.
The study will be conducted across ~40 hospitals, including Shanghai Chest Hospital. Phase I will assess safety, tolerability, and preliminary efficacy, determining the recommended phase II dose. Phase II will evaluate efficacy in cancers such as PDAC, CRC, and NSCLC, and investigate response/resistance mechanisms.
GenFleet's collaboration with Verastem Oncology, initiated in 2023, highlights the company's advances in RAS-targeted therapies, exemplified by previous success with KRAS G12C inhibitor fulzerasib.
Verastem Oncology (Nasdaq: VSTM) has begun a rolling submission of a New Drug Application (NDA) to the FDA for accelerated approval of the avutometinib and defactinib combination. This treatment is aimed at adult patients with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The submission will be completed in the second half of 2024 with mature data from the RAMP 201 trial, which shows promising response rates. Verastem plans to present this data at a medical conference and discuss potential approval paths for KRAS wild-type patients. The company will host an investor call on May 24, 2024, to provide updates.
Verastem Oncology (Nasdaq: VSTM) announced positive initial interim safety and efficacy results from its ongoing RAMP 205 Phase 1/2 clinical trial for metastatic pancreatic cancer. The trial evaluates avutometinib plus defactinib combined with gemcitabine and Nab-paclitaxel. As of May 14, 2024, in dose level 1, 83% (5/6) of patients achieved a confirmed partial response. One dose-limiting toxicity was observed but later cleared. The results will be presented at the ASCO Annual Meeting on June 1, 2024. Verastem will host a conference call on May 24, 2024, to discuss these findings.
Verastem Oncology reported positive business updates, including FDA Fast Track Designations for multiple combination therapies in cancer treatment and plans for upcoming clinical data presentations. Financially, the company ended the first quarter of 2024 with $110.1 million in cash, but reported an increased net loss compared to the same period in 2023.
Verastem Oncology (VSTM) will present at the RBC Capital Markets Global Healthcare Conference, demonstrating commitment to advancing cancer treatments. The management team will participate in a fireside chat on May 14, 2024. The webcast can be accessed on the company's website.
